See more : Surgical Science Sweden AB (publ) (SUS.ST) Income Statement Analysis – Financial Results
Complete financial analysis of Silk Road Medical, Inc (SILK) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Silk Road Medical, Inc, a leading company in the Medical – Devices industry within the Healthcare sector.
You may be interested
- Canamex Gold Corp. (CNMXF) Income Statement Analysis – Financial Results
- Orion Oyj (ORINY) Income Statement Analysis – Financial Results
- MTN Group Limited (MTN.JO) Income Statement Analysis – Financial Results
- Iconic Minerals Ltd. (BVTEF) Income Statement Analysis – Financial Results
- Burcon NutraScience Corporation (BRCNF) Income Statement Analysis – Financial Results
Silk Road Medical, Inc (SILK)
About Silk Road Medical, Inc
Silk Road Medical, Inc. operates as a medical device company in the United States. The company offers various products for the treatment of carotid artery disease called transcarotid artery revascularization. Its products include ENROUTE Transcarotid Neuroprotection System that is used to directly access the common carotid artery and initiate temporary blood flow reversal; ENROUTE Transcarotid Stent System, a self-expanding, self-tapering stent; ENHANCE Transcarotid Peripheral Access Kit for use in gaining initial access to the common carotid artery; and ENROUTE 0.014 Guidewire for navigating and crossing the target lesion for delivery of interventional devices. The company was incorporated in 2007 and is headquartered in Sunnyvale, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|
| Revenue | 177.13M | 138.64M | 101.48M | 75.23M | 63.35M | 34.56M | 14.26M |
| Cost of Revenue | 50.05M | 37.88M | 25.45M | 21.29M | 15.93M | 10.87M | 5.13M |
| Gross Profit | 127.09M | 100.76M | 76.03M | 53.94M | 47.43M | 23.68M | 9.13M |
| Gross Profit Ratio | 71.75% | 72.68% | 74.92% | 71.70% | 74.86% | 68.53% | 64.03% |
| Research & Development | 41.32M | 36.45M | 27.11M | 21.27M | 12.27M | 10.26M | 7.24M |
| General & Administrative | 144.57M | 115.97M | 96.17M | 75.33M | 62.86M | 34.82M | 20.26M |
| Selling & Marketing | 461.00K | 347.00K | 221.00K | 194.00K | 362.00K | 186.00K | 218.00K |
| SG&A | 145.03M | 116.32M | 96.39M | 75.52M | 63.22M | 34.82M | 20.26M |
| Other Expenses | 442.00K | -190.00K | -23.00K | -80.00K | -21.05M | -12.06M | 2.93M |
| Operating Expenses | 186.36M | 152.77M | 123.50M | 96.80M | 75.49M | 45.08M | 27.50M |
| Cost & Expenses | 236.41M | 190.64M | 148.94M | 118.09M | 91.42M | 55.95M | 32.63M |
| Interest Income | 9.96M | 2.53M | 198.00K | 1.10M | 1.66M | 189.00K | 34.00K |
| Interest Expense | 6.87M | 5.10M | 2.52M | 4.41M | 4.95M | 4.36M | 3.94M |
| Depreciation & Amortization | 3.79M | 3.17M | 1.92M | 1.39M | 1.29M | 517.00K | 128.72K |
| EBITDA | -45.08M | -46.74M | -45.55M | -41.47M | -46.17M | -32.75M | -18.25M |
| EBITDA Ratio | -31.32% | -35.82% | -46.61% | -55.51% | -41.68% | -94.78% | -107.20% |
| Operating Income | -59.27M | -52.00M | -47.47M | -42.86M | -28.07M | -21.40M | -18.37M |
| Operating Income Ratio | -33.46% | -37.51% | -46.78% | -56.97% | -44.30% | -61.91% | -128.87% |
| Total Other Income/Expenses | 3.53M | -3.01M | -2.34M | -4.51M | -24.35M | -16.24M | -982.00K |
| Income Before Tax | -55.74M | -55.01M | -49.81M | -47.37M | -52.42M | -37.63M | -19.36M |
| Income Before Tax Ratio | -31.47% | -39.68% | -49.09% | -62.96% | -82.73% | -108.89% | -135.76% |
| Income Tax Expense | 43.00K | 3.01M | 576.00K | 3.02M | 3.66M | -11.87M | 6.87M |
| Net Income | -55.74M | -58.02M | -50.39M | -50.39M | -56.07M | -37.63M | -19.36M |
| Net Income Ratio | -31.47% | -41.85% | -49.65% | -66.98% | -88.51% | -108.89% | -135.76% |
| EPS | -1.44 | -1.62 | -1.45 | -1.53 | -2.44 | -1.31 | -0.80 |
| EPS Diluted | -1.44 | -1.62 | -1.45 | -1.53 | -2.44 | -1.31 | -0.80 |
| Weighted Avg Shares Out | 38.80M | 35.78M | 34.64M | 32.97M | 22.96M | 28.71M | 24.05M |
| Weighted Avg Shares Out (Dil) | 38.80M | 35.78M | 34.64M | 32.97M | 22.96M | 28.71M | 24.05M |
Silk Road Medical's (SILK) New Launch to Aid Its TCAR Portfolio
Silk Road Medical (SILK) announces its latest launch of ENROUTE Transcarotid Neuroprotection System PLUS, which is likely to aid in TCAR procedures.
Silk Road Medical Strengthens TCAR Portfolio with Launch of ENROUTE Transcarotid Neuroprotection System PLUS
SUNNYVALE, Calif., April 02, 2024 (GLOBE NEWSWIRE) -- Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today announced the launch of its ENROUTE ® Transcarotid Neuroprotection System PLUS (“NPS PLUS”),...
Silk Road Medical (SILK) Upgraded to Buy: What Does It Mean for the Stock?
Silk Road Medical (SILK) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Silk Road Medical's (SILK) New Stent Expands Its TCAR Portfolio
Silk Road Medical (SILK) announces the launch of its Tapered ENROUTE Transcarotid Stent System to hospitals in the United States.
Silk Road Medical Expands TCAR® Portfolio with Launch of Tapered ENROUTE® Transcarotid Stent System
SUNNYVALE, Calif., March 05, 2024 (GLOBE NEWSWIRE) -- Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today announced that it has launched its Tapered ENROUTE Transcarotid Stent System to hospitals...
Silk Road Medical, Inc (SILK) Q4 2023 Earnings Call Transcript
Silk Road Medical, Inc (SILK) Q4 2023 Earnings Call Transcript
Silk Road Medical (SILK) Reports Q4 Loss, Tops Revenue Estimates
Silk Road Medical (SILK) came out with a quarterly loss of $0.33 per share versus the Zacks Consensus Estimate of a loss of $0.40. This compares to loss of $0.34 per share a year ago.
Silk Road Medical Reports Fourth Quarter and Full Year 2023 Financial Results and Provides 2024 Financial Outlook
SUNNYVALE, Calif., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today reported financial results for the three months and full year ended December...
Silk Road Medical to Report Fourth Quarter and Full Year 2023 Financial Results on February 28, 2024
SUNNYVALE, Calif., Feb. 07, 2024 (GLOBE NEWSWIRE) -- Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today announced it will report financial results for the fourth quarter and full...
Silk Road Medical (SILK) Stock Jumps 12.7%: Will It Continue to Soar?
Silk Road Medical (SILK) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Source: https://incomestatements.info
Category: Stock Reports